Profile data is unavailable for this security.
About the company
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on advancing targeted protein degradation science to create a new generation of small-molecule medicines that transform patients’ lives. By leveraging its proprietary Target ORiented ProtEin Degrader Optimizer (TORPEDO) platform, to design and optimize small molecule protein degraders that are active against their desired targets by harnessing the body’s natural process for destroying unwanted proteins. Its TORPEDO platform has the capability to design two types of protein degraders and both degrader approaches are reflected in its clinical pipeline. Its product candidate, CFT7455, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3, which are in clinical development for multiple myeloma and non-Hodgkin lymphoma. Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919.
- Revenue in USD (TTM)33.67m
- Net income in USD-105.50m
- Incorporated2015
- Employees145.00
- LocationC4 Therapeutics Inc490 Arsenal Way, Suite 120WATERTOWN 02472United StatesUSA
- Phone+1 (617) 231-0700
- Fax+1 (302) 655-5049
- Websitehttps://c4therapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ocugen Inc | 9.33m | -49.67m | 267.58m | 65.00 | -- | 6.56 | -- | 28.69 | -0.1839 | -0.1839 | 0.0351 | 0.14 | 0.1365 | -- | -- | 143,492.30 | -72.71 | -83.56 | -90.53 | -97.79 | -- | -- | -532.51 | -2,921.94 | -- | -- | 0.0663 | -- | 142.60 | -- | 27.33 | -- | 39.08 | -- |
| Mersana Therapeutics Inc | 34.84m | -74.62m | 272.34m | 123.00 | -- | 260.02 | -- | 7.82 | -0.6129 | -0.6129 | 0.286 | 0.0085 | 0.1611 | -- | 69.67 | 283,227.70 | -34.51 | -61.68 | -50.38 | -81.35 | -- | -- | -214.19 | -622.19 | -- | -- | 0.9604 | -- | 38.65 | 28.32 | 15.94 | -- | 9.61 | -- |
| Aclaris Therapeutics Inc | 27.08m | -37.00m | 282.87m | 91.00 | -- | 2.17 | -- | 10.45 | -0.5198 | -0.5198 | 0.3806 | 1.82 | 0.1352 | -- | 78.61 | 297,582.40 | -18.47 | -47.29 | -20.87 | -53.87 | 53.53 | 44.00 | -136.65 | -549.18 | -- | -- | 0.00 | -- | 5.03 | 38.41 | -1.81 | -- | -0.703 | -- |
| Aldeyra Therapeutics Inc | 0.00 | -44.80m | 283.46m | 10.00 | -- | 3.33 | -- | -- | -0.7538 | -0.7538 | 0.00 | 1.43 | 0.00 | -- | -- | 0.00 | -33.86 | -36.79 | -39.67 | -40.77 | -- | -- | -- | -- | -- | -- | 0.1522 | -- | -- | -- | 39.47 | -- | -- | -- |
| Vanda Pharmaceuticals Inc. | 190.86m | -16.39m | 285.71m | 203.00 | -- | 0.5279 | -- | 1.50 | -0.2824 | -0.2824 | 3.29 | 9.28 | 0.2967 | 9.30 | 5.30 | 940,187.20 | -2.55 | 6.61 | -2.95 | 7.62 | 93.62 | 90.55 | -8.59 | 15.18 | 4.84 | -- | 0.00 | 0.00 | -24.27 | -0.0496 | -60.02 | -36.96 | -56.77 | -- |
| C4 Therapeutics Inc | 33.67m | -105.50m | 285.89m | 145.00 | -- | 1.18 | -- | 8.49 | -1.70 | -1.70 | 0.5217 | 3.44 | 0.095 | -- | 6.21 | 232,193.10 | -29.76 | -25.91 | -33.20 | -29.45 | -- | -- | -313.35 | -292.35 | -- | -- | 0.00 | -- | -33.25 | 1.40 | -3.37 | -- | -8.68 | -- |
| iTeos Therapeutics Inc | 35.00m | -121.25m | 286.70m | 157.00 | -- | 0.4539 | -- | 8.19 | -3.15 | -3.15 | 0.9064 | 17.29 | 0.05 | -- | 1.43 | 222,929.90 | -17.31 | 5.84 | -18.16 | 7.02 | -- | -- | -346.44 | 22.09 | -- | -- | 0.00 | 0.00 | -95.29 | -- | -216.54 | -- | 68.45 | -- |
| Lyell Immunopharma Inc | 63.00k | -203.99m | 287.60m | 224.00 | -- | 0.498 | -- | 4,565.04 | -0.8013 | -0.8013 | 0.0003 | 2.07 | 0.00009 | -- | -- | 281.25 | -28.85 | -- | -30.32 | -- | -- | -- | -323,792.10 | -- | -- | -- | 0.00 | -- | -99.85 | -- | -28.13 | -- | -- | -- |
| Rezolute Inc | 0.00 | -69.31m | 290.29m | 59.00 | -- | 2.45 | -- | -- | -1.27 | -1.27 | 0.00 | 2.05 | 0.00 | -- | -- | 0.00 | -58.64 | -50.36 | -62.66 | -53.25 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.19 | -- | -- | -- |
| Lexicon Pharmaceuticals Inc | 5.23m | -216.39m | 291.87m | 285.00 | -- | 1.64 | -- | 55.82 | -0.7513 | -0.7513 | 0.018 | 0.4938 | 0.0175 | 0.6955 | 3.25 | 18,347.37 | -72.42 | -24.41 | -81.77 | -29.01 | 93.54 | 98.49 | -4,138.33 | -84.92 | 7.43 | -12.32 | 0.3588 | -- | 766.19 | -54.71 | -73.74 | -- | 37.68 | -- |
| Voyager Therapeutics Inc | 163.78m | 25.88m | 292.30m | 162.00 | 9.12 | 0.8851 | 9.45 | 1.78 | 0.5876 | 0.5876 | 2.94 | 6.06 | 0.4545 | -- | 14.29 | 1,011,012.00 | 7.18 | 0.6378 | 8.42 | 0.8203 | -- | -- | 15.80 | 1.30 | -- | -- | 0.00 | 0.00 | 511.16 | 101.01 | 385.14 | -- | -5.43 | -- |
| Nautilus Biotechnology Inc | 0.00 | -70.21m | 293.82m | 161.00 | -- | 1.31 | -- | -- | -0.561 | -0.561 | 0.00 | 1.78 | 0.00 | -- | -- | 0.00 | -24.29 | -- | -25.05 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.93 | -- | -- | -- |
| SAGE Therapeutics Inc | 106.40m | -337.59m | 300.36m | 487.00 | -- | 0.5443 | -- | 2.82 | -5.58 | -5.58 | 1.76 | 9.02 | 0.1354 | -- | 5.24 | 218,478.40 | -42.95 | -21.88 | -48.97 | -23.30 | 91.75 | 99.63 | -317.29 | -131.50 | -- | -- | 0.00 | -- | 1,024.84 | -0.8606 | -1.63 | -- | -28.01 | -- |
| Absci Corp | 4.21m | -97.67m | 304.33m | 155.00 | -- | 1.52 | -- | 72.34 | -0.9357 | -0.9357 | 0.0402 | 1.76 | 0.0178 | -- | 3.66 | 27,141.94 | -41.42 | -- | -46.85 | -- | -- | -- | -2,321.56 | -- | -- | -157.35 | 0.0269 | -- | -0.5046 | -- | -5.40 | -- | -- | -- |
Data as of Nov 21 2024. Currency figures normalised to C4 Therapeutics Inc's reporting currency: US Dollar USD
60.12%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Lynx1 Capital Management LPas of 30 Sep 2024 | 6.88m | 9.92% |
| Soleus Capital Management LP (Investment Management)as of 30 Sep 2024 | 6.60m | 9.52% |
| Wasatch Advisors LPas of 30 Sep 2024 | 5.68m | 8.19% |
| RA Capital Management LPas of 30 Sep 2024 | 4.88m | 7.04% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 4.27m | 6.16% |
| Commodore Capital LPas of 30 Sep 2024 | 3.41m | 4.92% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 3.33m | 4.80% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 2.81m | 4.05% |
| Morgan Stanley & Co. LLCas of 30 Sep 2024 | 2.28m | 3.28% |
| BofA Securities, Inc.as of 30 Sep 2024 | 1.55m | 2.24% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
